Metered Dose Inhaler Devices Market Growth Outlook For 2026: Drivers, Trends And Future Opportunities
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Metered Dose Inhaler Devices Market Forecast: Value Set To Climb From $17.12 Billion To $21.06 Billion
The metered dose inhaler devices market has experienced robust expansion in recent years. Its valuation is predicted to climb from $16.23 billion in 2025 to $17.12 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.5%. This past growth can be ascribed to factors such as the increasing prevalence of asthma, a rise in COPD incidence, the widespread application of inhalation therapy, physician preference for MDIs, and the availability of generic inhalers.
The metered dose inhaler devices market size is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $21.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this anticipated growth include the rise of smart inhalers, stringent environmental regulations concerning propellants, the expansion of homecare treatments, increasing demand for digital adherence monitoring, and the advent of new respiratory therapies. Key trends identified for this period encompass smart dose tracking inhalers, the development of breath-actuated inhalation technology, more compact and portable device designs, improvements in dose accuracy, and the wider adoption of eco-friendly propellants.
Get A Free Sample Report With In-Depth Market Insights:
Metered Dose Inhaler Devices Market Growth Drivers: What’s Behind The Acceleration?
The metered dose inhaler devices market is anticipated to grow due to the increasing prevalence of chronic obstructive pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterized by obstructed airflow, typically caused by long-term exposure to irritants like cigarette smoke, leading to symptoms such as shortness of breath, coughing, and wheezing. The rising incidence of COPD is influenced by factors including tobacco use, air pollution, an aging population, and delayed diagnosis or treatment. Metered dose inhaler (MDI) devices assist in managing COPD by delivering medication directly to the lungs, offering rapid relief and improving airflow. For example, in December 2023, the National Institutes of Health, a US-based government agency, projected that COPD cases would increase from 532 million in 2030 to a total of 592 million by 2050. Consequently, the increasing prevalence of chronic obstructive pulmonary diseases is propelling the growth of the metered dose inhaler devices market. The rising air pollution is expected to boost the growth of the metered dose inhaler (MDI) devices market going forward. Air pollution refers to the presence of harmful substances, including particulate matter, gases, and biological molecules, in the atmosphere that can cause adverse health effects. Exposure to air pollution is a significant risk factor for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The increase in air pollution is largely attributed to industrialization, urbanization, higher vehicular emissions, and the burning of fossil fuels. MDIs support public health by providing targeted medication to manage respiratory conditions that are triggered or worsened by polluted air. For instance, in October 2025, the Clean Air Fund, a UK-based nonprofit philanthropic organization, reported that in 2023, funding for fossil fuel–related projects surged 80%, increasing from $5.3B to $9.5B due to rising air pollution. Additionally, fossil fuel combustion contributes to over 5 million of the 8.1 million annual premature air pollution deaths. Therefore, the rising air pollution is driving the growth of the metered dose inhaler devices market.
Metered Dose Inhaler Devices Market Segment Landscape And Growth Outlook
The metered dose inhaler devices market covered in this report is segmented –
1) By Type: Desktop Metered Dose Inhaler Devices, Portable Metered Dose Inhaler Devices, Other Types
2) By Distribution Channel: Online, Offline
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Other Applications
4) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Desktop Metered Dose Inhaler Devices: Standard desktop MDI devices, High-performance desktop MDI devices, Smart desktop MDI devices
2) By Portable Metered Dose Inhaler Devices: Conventional portable MDI devices, Advanced portable MDI devices, Smart portable MDI devices
3) By Other Types: Nebulizer-Based MDI devices, Dry powder inhaler (DPI) combined devices, Soft mist inhaler (SMI) devices, Other specialized MDI devices
Metered Dose Inhaler Devices Market Trends: What’s Defining The Industry’s Next Phase?
Major companies in the metered dose inhaler devices market are concentrating on developing technologically advanced solutions, such as pressurized metered dose inhalers, to improve drug delivery efficiency and patient compliance. Pressurized metered-dose inhalers (pMDIs) are devices for inhalation that deliver an exact dose of medication in aerosol form using a pressurized propellant. For instance, in July 2023, Lupin Limited, an India-based pharmaceutical company, introduced Luforbec 100/6, a pressurized metered dose inhaler (pMDI) designed for treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This product combines beclometasone (100 µg) and formoterol (6 µg), offering an effective treatment option for patients who require combination therapy. Importantly, Luforbec is priced approximately 47% lower than the fixed reference price, thereby increasing its accessibility. Given that asthma impacts about 5% of adults in Germany, this launch emphasizes Lupin’s commitment to addressing critical healthcare requirements and enhancing patient outcomes in the field of respiratory care.
Metered Dose Inhaler Devices Market Competitive Overview And Top Companies
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB
View The Full Metered Dose Inhaler Devices Market Report:
Metered Dose Inhaler Devices Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the metered dose inhaler devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
